Objectives: The development and transmission of extensively drug-resistant (XDR) tuberculosis (TB) constitutes a serious threat to the effective control of TB in several countries. Here, in an attempt to further elucidate the dynamics of the acquisition of resistance to second-line drugs and investigate an eventual role for eis promoter mutations in aminoglycoside resistance, we have studied a set of multidrug-resistant (MDR)/XDR-TB isolates circulating in Lisbon, Portugal.
Introduction
Extensively drug-resistant (XDR) tuberculosis (TB) is a consequence of multiple acquisitions of mutations in specific resistance-associated genes. Such mutations may interfere with drug -target interactions or cause overexpression of the protein target or drug modification enzymes. Since XDR-TB is defined as TB having resistance to isoniazid and rifampicin plus resistance to a fluoroquinolone and a second-line injectable antibacillary drug (capreomycin, amikacin or kanamycin), the most frequently implicated genes are inhA, katG, rpoB, gyrA, rrs, tlyA and eis. 1 -3 According to the latest drug resistance surveillance report from the WHO, XDR-TB cases have already been reported in over 58 countries. The worldwide occurrence of XDR-TB raises serious public health concerns, as this level of cumulative resistance to the most effective and available antibacillary drugs is most often found to be untreatable. 4 In Portugal, the high XDR-TB rates in its capital city, Lisbon, which is also the region with the highest TB incidence, have been shown to be mainly associated with particular genetic clusters that have undergone extensive clonal expansion in the community. Of special importance are the strains belonging to some of the Lisboa family genetic clusters that have been in circulation for almost two decades. XDR-TB in the region has been considered a serious public health concern in the years following the first definition of XDR-TB, but recent studies now show that this is an old problem that can be traced back to the 1990s, at least. 5, 6 However, a considerable degree of undernotification exists in the country, as only 26-55 new cases of multidrug-resistant (MDR) TB and 2-13 of XDR-TB have been reported each year by the Portuguese Health Authorities between 2000 and 2010, nationwide. 7 The main genetic clusters associated with MDR-TB and XDR-TB in Lisbon, designated Lisboa3 and Q1, have been described in previous publications. The Lisboa3 cluster was originally described in the 1990s and was highly associated with the original MDR-TB outbreak in the region and presently with XDR-TB. The Q1 cluster, first described from strains recovered in 2003, is genetically very close to the original Lisboa family and contains XDR-TB strains, although it presents less mutational diversity than the Lisboa3 cluster. 6,8 -10 The exact phylogenetic origin of this later cluster with respect to the Lisboa family is still under study, as there are significant genetic differences regarding other genomic loci or spoligotyping profiles (J. Perdigão and I. Portugal, unpublished data).
Previous data from our laboratory have contributed to elucidate the molecular basis of resistance development among MDR-TB and XDR-TB strains in the region through the mutational analysis of gyrA, rrs and tlyA. 9 However, the mode of resistance acquisition and the genetic determinants leading to second-line aminoglycoside resistance in the region are not fully understood. Combining both mutational and genotypic approaches will eventually lead to insight into how resistance develops and allow further strain discrimination for the study of transmission in the community. 10 Zaunbrecher et al.
11 associated promoter mutations in eis with kanamycin resistance. The gene product of eis, an acetyltransferase, catalyses the multiacetylation of aminoglycosides, modifying kanamycin and, with lower affinity, amikacin. The explanation offered by the authors suggested that eis promoter mutations are responsible for kanamycin-resistant isolates that do not present cross-resistance to amikacin. 11, 12 Here, in attempt to further elucidate the dynamics of resistance acquisition and investigate an eventual role for eis promoter mutations in second-line aminoglycoside resistance, we have studied a set of MDR/XDR-TB isolates that included some of the original strains involved in the Lisbon MDR-TB outbreak from the 1990s. 6 
Methods

Clinical isolates, drug susceptibility testing (DST) and genotyping
A total of 44 MDR/XDR Mycobacterium tuberculosis clinical isolates recovered from TB patients in the Lisbon region, between 1997 and 2009, were studied. All strains were isolated at local hospital units and laboratories and sent for DST at level 3 mycobacteriology laboratories. For strains isolated in 1997 -98 and in 2005, only DNA was available for mutational analysis and genotyping. All available XDR-TB isolates from 2005 were included in the study; available MDR-TB isolates from the 1990s were included for comparison with more recent isolates. Also, all MDR/ XDR-TB isolates received in our laboratory during 2008-10 and available at the time of the study were included.
At the time of isolation, first-line DST for isolates recovered between 1997 and 1998 was performed using the radiometric BACTEC TM 
Mutational analysis of drug resistance-associated genes
A 981 bp fragment, containing tlyA gene, was amplified by PCR using the tlyAF3 (5 ′ -AAGGCATCGCACGTCGTCTTTCC-3 ′ ) and tlyAR3 (5 ′ -TGTCGCC CAATACTTTTTCTACGC-3 ′ ) primers. The cycling conditions were as follows: denaturation at 948C for 4 min; 35 cycles of denaturation at 948C for 1 min, annealing at 588C for 1 min and extension at 728C for 2 min and 30 s; and a final extension step at 728C for 10 min.
The region between positions 1151 and 1590 of the rrs gene was amplified by PCR using primers RRS2-
The cycling conditions were as follows: denaturation at 948C for 4 min; 35 cycles of denaturation at 948C for 1 min, annealing at 588C for 1 min and extension at 728C for 2 min and 30 s; and a final extension step at 728C for 10 min.
A 601 bp fragment, containing the promoter region of the eis gene, was amplified from all isolates by PCR using eisF1 (5 ′ -GCCAT GGGACCGGTACTTGC-3 ′ ) and eisR1 (5 ′ -GTAGATGCCGCCCTCGCTAG-3 ′ ) oligonucleotide primers. The cycling conditions were as follows: denaturation at 948C for 5 min; 35 cycles of denaturation at 948C for 1 min, annealing at 568C for 1 min and extension at 728C for 1 min and 30 s; and a final extension step at 728C for 10 min.
An internal 320 bp (78 -397) fragment of the gyrA gene was amplified by PCR with the oligonucleotide primers gyrA-F (5 ′ -CAGCTACA TCGACTATGCGA-3 ′ ) and gyrA-R (5 ′ -GGGCTTCGGTGTACCTCAT-3 ′ ). The cycling conditions were as follows: denaturation at 948C for 4 min; 35 cycles of denaturation at 948C for 1 min, annealing at 558C for 1 min and extension at 728C for 1 min; and a final extension step at 728C for 10 min.
Crude DNA extracts of each isolate were used in all molecular biology reactions. Prior to sequencing, the amplified fragments were purified using MSB w Spin PCRapace (Invitek w ). Sequencing reactions and capillary electrophoresis were outsourced to Macrogen Inc. using primers eisF1, RRS2-R, gyrA-F, tlyAF1 (5 ′ -GTTGTTGGCCGCCCTGGAGT-3 ′ ) and tlyAR1 (5 ′ -GGTCTCGGTGGCTTCGTCGC-3 ′ ), as appropriate.
Amikacin and kanamycin MICs
Amikacin and kanamycin MICs for selected isolates were determined using the resazurin microplate assay (REMA) system, as described by Martin et al. 15 Selected isolates were tested in duplicate for growth at serial 2-fold dilutions of both antibacillary drugs at concentrations ranging between 80 and 0.08 mg/L. Growth controls with no drug and a sterility control were included in each plate assay. 16 Perdigão et al.
Results
Mutations in second-line drug resistance-associated genes
In the present study, 44 MDR/XDR-TB strains were analysed, 7 of which were isolated during the MDR-TB outbreak identified in the 1990s. For all isolates, we have analysed four genes associated with XDR criteria of resistance, injectable second-line drugs and fluoroquinolones: rrs, tlyA, eis and gyrA.
In the rrs gene, six different mutations were found, including two insertions ( Table 1 ). The most prevalent mutation found in the rrs gene was A1401G (13/40), a classical mutation associated with kanamycin, amikacin and capreomycin resistance, which was highly associated with the Q1 cluster as previously reported. 8 This mutation was also found in one Lisboa3 isolate from 1998.
The mutational analysis of tlyA has revealed four different mutations: one missense mutation, one nonsense mutation and two frameshift mutations. All mutations detected in the tlyA gene were detected in the Lisboa3 cluster only, the most prevalent being a frameshift GT insertion at position 755 found in 13 isolates.
The screening of the eis promoter region, more recently shown to be associated with kanamycin resistance, resulted in the finding of one mutation only, G-10A, previously shown by Zaunbrecher et al. to cause overexpression of the eis gene. 11 This mutation was found in Lisboa3 isolates (19/27) .
Comparing the amikacin and kanamycin phenotypic resistance profiles, we observed that of the 17 isolates with secondline DST data with the eis G-10A mutation, 9 were resistant to kanamycin alone, 4 were resistant to both kanamycin and amikacin and 4 were susceptible to both (Table 1) .
This observation leads to questions concerning the molecular basis of amikacin resistance when no rrs mutations are found. According to the published work by Zaunbrecher et al., 12 eis promoter mutations may cause resistance to kanamycin but not amikacin. We have found, however, that isolates bearing eis G-10A mutations might be resistant to both kanamycin and amikacin, resistant to kanamycin only or susceptible to both. One hypothesis is that the level of kanamycin or amikacin resistance is lower than the level of resistance conferred by rrs mutations. If this low-level resistance is close enough to the tested critical concentration it might yield discrepant results independent of its genotype but dependent on the methodology employed in DST. To investigate this hypothesis, we determined the kanamycin and amikacin MICs for selected isolates bearing different mutations using the REMA methodology (Table 2) . We found that all tested isolates bearing rrs A1401G mutations exhibited high-level resistance (.80 mg/L) to both amikacin and kanamycin. The results obtained for the two isolates bearing the eis G-10A mutation yielded slightly different results, with one isolate exhibiting an MIC of 5 mg/L for kanamycin (equal to the critical concentration used in the MGIT TM 960 system) and 0.63 mg/L for amikacin (below the critical concentration used in the MGIT TM 960 system). The other isolate exhibited kanamycin and amikacin MICs (10 and 1.25 mg/L, respectively) above the critical concentrations used in kanamycin and amikacin DST ( Table 2 ). Both isolates initially tested susceptible to amikacin and kanamycin (Table 1) , which may corroborate the proposed hypothesis that eis G-10A mutations may cause lowlevel resistance and discrepant DST results, especially in the case of amikacin DST. It is important to stress the fact that the REMA methodology is susceptible to phenotypic variations and presents difficulties in obtaining accurate readings at low-level concentrations. 13 Nevertheless, in all plate assays, M. tuberculosis H37Rv was used as a susceptible control strain and to establish the baseline MIC for comparison of the resistance levels.
In the gyrA gene, six different mutations were found, three of which occurred in codon 94. Except for one synonymous mutation, all mutations detected in this gene were missense mutations and were cluster associated. The D94A mutation occurred only in the Q1 cluster, whereas S91P and D94G were associated only with the Lisboa3 cluster. A non-clustered isolate recovered in 1997 and having an unknown second-line resistance profile was found to have mutation D94N, previously associated with fluoroquinolone resistance, although no second-line susceptibility results were available for this strain. The H70R mutation found in another non-clustered isolate (HVNG1) could not be associated with fluoroquinolone resistance, since the isolate is susceptible to ofloxacin.
Genotypic comparison reveals clonality and resistance acquisition dynamics
The overall isolate distribution through the Q1 and Lisboa3 clusters allowed the following observations: in the Q1 cluster (except for one isolate), one mutation only (rrs A1401G) ensures resistance to all three second-line injectable drugs, with no mutation detected in the eis and tlyA genes. Moreover, in the Q1 cluster, two mutational events, in rrs and gyrA, were enough for an MDR-TB strain to become XDR in two mutational steps. With the current panel of isolates it is impossible to determine which resistance was acquired first, since all isolates with the rrs A1401G mutation also have the gyrA D94A mutation.
In the Lisboa3 cluster, however, it is possible to establish the dynamics of resistance acquisition. The mutational analysis itself allowed the discrimination of the entire cluster, as shown by the intracluster mutational diversity. We observed that whenever a mutation was present in the tlyA gene, no classical rrs mutation (A1401G, C1402A/T or G1484T) was detected. In addition, Lisboa3 cluster isolates with a tlyA mutation also had an eis mutation (G-10A) ( Table 1) .
Discussion
In the present study, we have analysed second-line drug resistance-associated genes in 44 MDR/XDR-TB clinical isolates, of which 40 belong to two different high-prevalence clusters. The Lisboa3 cluster was first described in the 1990s as already associated with MDR, and later with XDR, while the Q1 cluster was described in a study involving strains from 2003 as a more homogeneous cluster, from a mutational standpoint, and already associated with MDR and XDR. 6, 8, 9 Looking at the second-line resistance profiles (specifically, resistance to kanamycin, amikacin and capreomycin), we found that in the Q1 cluster (except for one isolate) the acquisition of resistance to these three injectable second-line drugs was caused by a single mutational event (rrs A1401G); however, Development of XDR-TB in Lisbon, Portugal Perdigão et al.
in the Lisboa3 cluster, our data suggest that resistance to kanamycin and amikacin was acquired first, through an eis hypermorphic mutation, and, at a later stage, resistance to capreomycin was acquired due to tlyA mutations. Therefore, these genetic clusters illustrate single and multistep processes of resistance development by strains that were subsequently transmitted in the community, generating primary XDR-TB cases. Such observations allow the establishment of a putative model for the resistance acquisition pattern in the Lisboa3 cluster (Figure 1) . This model consists of a multistep process that is more extensive than the one observed in the Q1 cluster. We propose that in the Lisboa3 cluster an MDR strain initially acquired resistance to kanamycin and then acquired fluoroquinolone resistance, twice and independently, which was followed by capreomycin resistance acquisition through multiple events and, finally, acquisition of a higher level of resistance to amikacin, kanamycin and capreomycin through an rrs A1401G mutation. The only strain (FF359) to exhibit this later step of resistance acquisition was isolated in 1998 and its dissemination was most probably contained, since no Lisboa3 isolate with an rrs A1401G mutation has been found in recent years. For the Lisboa3 strains bearing the gyrA S91P and tlyA Ins755GT mutations, it is impossible to determine whether fluoroquinolone resistance was acquired first before capreomycin resistance or vice versa, since all strains with one of these mutations also have the other. It is noteworthy that two out of seven strains isolated between 1997 and 1998 and involved in the original Lisbon MDR-TB outbreak described by us already had, at the time, the mutational profile of recent circulating strains. 6 Second-line DST and patient treatment outcomes were not available for these strains, but the fact that some isolates exhibit the Lisboa3 characteristic rrs, tlyA and gyrA mutations indicates that they were most likely XDR-TB strains at that time. This highlights an established XDR-TB problem that has been present in the Lisbon Health Region for almost two decades.
The pattern and proposed resistance acquisition dynamics described above illustrate the need for more efficient MDR/ XDR-TB management in two different aspects. First, the need to contain specific clusters or families of strains associated with MDR/XDR-TB; such containment should be supported by better contact tracing for affected individuals and more rapid and reliable diagnostics. Positive contacts of the presumed index case would ideally be treated in an inpatient mode (until sputum smear conversion), in negative-pressure isolation wards, using a tailored second-line drug regimen based on the DST results from the presumed index contact until DST becomes available. Given the time-consuming culture and DST of M. tuberculosis, several rapid molecular diagnosis systems have become available. However, MDR-TB molecular diagnosis per se is of no use if information regarding susceptibility to second-line drugs is not available. Although the initiation of an empirical or standardized treatment is sometimes the only available option, it may result in further drug resistance development, and this is highlighted by the dynamics shown in the present study, in which two mutational events are enough for a strain to become XDR. The necessary tools to perform such molecular testing in a setting-adapted approach are sometimes not readily available commercially and, still, before implementation of these commercial tests it is necessary to determine the local applicability due to the geographical variability of resistanceassociated mutations. As the body of knowledge concerning new mutations and drug resistance-associated genes expands, it will be gradually easier to associate both the genotype and phenotype.
Another aspect to consider is the issue of mismanagement of drug therapy, poor regimen implementation, poor compliance or default, which lead to cumulative resistance acquisition. Although the high prevalence of XDR-TB in the region illustrates the need for new drugs and new drug regimens for MDR/ XDR-TB treatment, special care must be taken in the introduction of new drugs in TB treatment. 17 The additional emergence of resistance to new compounds may render these drugs ineffective in a short time period. 18, 19 Step 1 Step 3 Figure 1 . Multistep process of resistance acquisition dynamics in the Lisboa3 cluster. The scheme represents the process through which XDR has most likely been acquired multiple independent times in a maximum of three steps.
Step 1 consists of the acquisition of low-level kanamycin (KAN) resistance through an eis G-10A mutation, followed by the acquisition of fluoroquinolone (FQ) resistance by a gyrA D94G or S91P mutation, although regarding the strains with the S91P mutation it is impossible to ascertain whether FQ resistance or capreomycin (CAP) resistance was acquired in the first place. Strains with the gyrA D94G mutation acquired CAP resistance multiple times through different mutations in the tlyA gene. One strain was found to have acquired CAP and KAN resistance through an rrs A1401G mutation, thus strengthening the KAN resistance. AMK, amikacin. Zaunbrecher et al. 12 proposed that eis promoter mutations would be associated with kanamycin resistance only, therefore explaining the lack of cross-resistance between kanamycin and amikacin in some clinical isolates. Although in such cases an increase in the level of amikacin resistance was observed, the strains were phenotypically considered susceptible. The question remains if the degree of amikacin resistance conferred by eis promoter mutations has clinical relevance and impairs chemotherapy; if so, is it detectable by DST? Our data show that four isolates containing the eis G-10A mutation and no rrs mutations were phenotypically resistant to amikacin and kanamycin. Is it therefore possible that the degree of amikacin resistance may be close enough to the critical concentration used in DST to result in undetectable low-level resistance?
Furthermore, we have determined the kanamycin and amikacin MICs for selected strains and the data obtained corroborate the hypothesis that the increase in the kanamycin MIC for eis G-10A isolates is accompanied by a smaller amikacin MIC increase. A 2-fold increase in the amikacin MIC, when compared with the amikacin MIC for M. tuberculosis H37Rv, is not as significant as the increase in the kanamycin MIC, but it may be sufficient to confer borderline/undetectable resistance and, hence, explain discrepant or inconsistent results. The same may happen with kanamycin DST, as one strain exhibited a 4-fold increase and another strain an 8-fold increase in the kanamycin MIC. Supporting this, Engstrom et al. 20 have reported the occurrence of eis G-10A mutations among kanamycin-susceptible isolates, which may be due to the low-level resistance conferring MICs close to the critical concentration used in DST. Similarly, Campbell et al. 21 reported that in 111 kanamycin-resistant isolates, 32% had eis mutations, with no isolate accumulating rrs and eis mutations simultaneously. Moreover, the authors also reported one isolate resistant to kanamycin and amikacin with an eis promoter mutation only. In a study by Feuerriegel et al., 22 10 amikacin-and capreomycin-resistant isolates did not show any mutation in the rrs and tlyA genes, and the same was true for strains resistant to amikacin alone. One possible explanation is that amikacin resistance in these isolates is mediated by eis promoter mutations. The authors, however, did not test the isolates for susceptibility to kanamycin, which would help to clarify this mechanism. In fact, current directives from the Portuguese Health Authorities state that second-line DST is not mandatory for kanamycin, only for amikacin and capreomycin. Nonetheless, as confirmed by this study, it is important to stress that susceptibility to amikacin does not imply susceptibility to kanamycin. In our opinion, kanamycin DST is of great importance, as kanamycin resistance alone may be associated with undetectable low-level amikacin resistance, which may eventually impact on the clinical outcome or resistance development. The non-simultaneous occurrence of eis and rrs mutations in more recent isolates, representing a genetic cluster (Lisboa3) circulating for over a decade, suggests that mutations in either of these genes are sufficient to confer phenotypic resistance in the host and impair clinical treatment. Otherwise, at this stage of the epidemic, we would expect to find Lisboa3 strains that have acquired high-level amikacin and kanamycin resistance.
Also recently, data from Kim et al. 23 show that the Eis protein has an important role in the suppression of the host immune system through the acetylation of DUSP16/MKP-7, inhibiting the inhibition of JNK-dependent autophagy, phagosome maturation and reactive oxygen species generation. This important immunomodulatory property of Eis combined with its overexpression might be responsible for an increased virulence phenotype and be a clue to explain the high prevalence and persistence of certain Lisboa family strains in the region.
